Overview

Tirofiban for Patients Treated With Alteplase

Status:
Terminated
Trial end date:
2020-08-31
Target enrollment:
Participant gender:
Summary
After intravenous thrombolysis, the overall recanalization rate is 46%, and recclusion after initial recanalization occurs in 14-34%. In the MR TEA, the investigators compared the effects of administration of tirofiban in acute ischemic stroke patients treated with intravenous alteplase thrombolysis with alteplase alone.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Capital Medical University
Treatments:
Tirofiban
Tissue Plasminogen Activator